Relationship between esomeprazole dose and timing to heartburn resolution in selected patients with gastroesophageal reflux disease.

ABSTRACT:

Objective

To increase response rates to therapy by increasing the dosage of proton pump inhibitor (PPI) therapy in patients with gastroesophageal reflux disease (GERD) whose symptoms are predominantly associated with acid reflux.

Methods

In this double-blind, randomized, proof-of-concept study, 369 patients with GERD and moderate heartburn lasting ≥three days/week, a history of response to antacids/acid suppression therapy, and a positive esophageal acid perfusion test result were randomized to esomeprazole 20 or 40 mg once daily, or to 40 mg twice daily for four weeks. Heartburn symptom relief/resolution was subsequently evaluated.

Results

In this study population, no relationship was apparent between esomeprazole dosage and efficacy variables for sustained heartburn

SUBMITTER: Orlando RC 

PROVIDER: S-EPMC3108657 | biostudies-literature | 2010

REPOSITORIES: biostudies-literature